{"filings":[{"id":2006236,"accession_number":"0001711279-26-000058","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-08-03T11:04:02+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.","Net income $54.8M ($1.85 basic EPS) vs $38.3M ($1.33) in Q2 2025.","Cash and investments $1.1B; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.","KB803 (ophthalmology) IOLITE study fully enrolled; top-line data expected 4Q 2026.","KB407 (CF) interim results expected before year end; FDA alignment on registrational study design expected 4Q 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":3.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":235579000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1777876,"accession_number":"0001711279-26-000050","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-07-21T21:24:31+00:00","items":["8.01","9.01"],"status":"ready","headline":"Krystal Biotech discloses single-patient data from discontinued KB801 study in patent response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed response to USPTO Office Action for KB801 patent application; included data from one patient in discontinued clinical study.","Patient experienced complete closure of persistent corneal epithelial defect after KB801 treatment.","Study discontinued to advance KB801 into pivotal trial; no safety concerns or serious adverse events observed.","Company cautions that single-patient observation is not top-line results and no conclusions on safety/efficacy should be drawn.","Pivotal trial results for KB801 expected to be reported in ordinary course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":535561,"accession_number":"0001711279-26-000047","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-05-20T00:08:52+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech shareholders approve all four proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Krish S. Krishnan and Christopher Mason as Class III directors with ~89% and ~84% of votes cast.","Ratified KPMG as independent auditor for FY2026 with over 99.9% of votes in favor.","Advisory vote on named executive officer compensation passed with ~95.5% of votes cast.","Approved non-employee director compensation policy with ~90% of unaffiliated votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94902,"accession_number":"0001711279-26-000044","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.","Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.","FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.","KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.","FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating."],"consensus_eps_estimate":null,"consensus_eps_actual":1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":116357000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107602,"accession_number":"0001711279-26-000018","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.","FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.","Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.","Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.","VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed."],"consensus_eps_estimate":null,"consensus_eps_actual":6.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":389130000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107601,"accession_number":"0001711279-26-000008","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.","Cash, equivalents and investments ~$955M as of Dec 31, 2025.","Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.","2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).","Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts."],"consensus_eps_estimate":null,"consensus_eps_actual":6.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":389130000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107600,"accession_number":"0001711279-26-000005","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech KB407 Phase 1 positive: CFTR delivery confirmed in all 6 biopsied patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations (modulator ineligible).","Transduction rates ranged 29.4% to 42.1% across six patients; all biopsies positive for CFTR or viral marker.","KB407 well tolerated; one SAE (asthma exacerbation) deemed procedure-related, resolved in 5 days.","Registrational CORAL-3 study design submitted to FDA; enrollment expected 1H 2026 after alignment.","Four of seven highest-dose patients were modulator ineligible; data supports mutation-agnostic potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123965,"accession_number":"0001711279-25-000092","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Krystal Biotech director Kirti Ganorkar resigns effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kirti Ganorkar resigned from Krystal Biotech Board on Dec 22, 2025 due to time constraints from promotion to Managing Director at Sun Pharma.","Resignation not due to disagreement with Board or management; effective Dec 31, 2025.","Ganorkar served on Board since company's IPO in September 2017.","Board thanks him for contributions; no successor identified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123964,"accession_number":"0001711279-25-000088","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.","FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.","VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.","FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.","CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused."],"consensus_eps_estimate":null,"consensus_eps_actual":5.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":282025000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123963,"accession_number":"0001711279-25-000082","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.","VYJUVEK added to Japan's National Health Insurance Drug Price List at 2,955,232.7 yen per unit.","Drug indicated for dystrophic epidermolysis bullosa, a rare genetic skin disorder.","Launch follows NHI listing, enabling patient access with government reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140636,"accession_number":"0001711279-25-000078","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.","Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.","Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.","VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.","First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":184225000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140635,"accession_number":"0001711279-25-000071","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.","First genetic medicine approved in Japan for DEB; allows home dosing and administration by patients or family.","Based on Phase 3 data and Japanese open-label extension; all 4 patients achieved full wound closure at 6 months.","Re-examination period is 10 years; launch expected in Japan by end of 2025.","Previously approved in US (May 2023) and EU (April 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140634,"accession_number":"0001711279-25-000069","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.","81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.","Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.","Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.","KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140633,"accession_number":"0001711279-25-000065","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.","Study enrolls up to 27 adults with Stage 2 or 3 NK; 2:1 randomized to KB801 or placebo twice weekly for 8 weeks.","Primary endpoint: safety/tolerability; secondary: complete durable corneal healing at week 8.","NK diagnosed claims in US rose 115% from ~31,000 (2020) to ~68,000 (2024), per claims data.","Investor call/webcast July 9 at 8:30am ET to discuss KB801 program and trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158346,"accession_number":"0001711279-25-000055","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).","Median DOR and PFS not reached; responses durable.","Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.","Combination cohort with pembrolizumab enrolling for NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158345,"accession_number":"0001711279-25-000051","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech stockholders elect Class II directors, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Daniel S. Janney, Dino A. Rossi, and E. Rand Sutherland as Class II directors for three-year terms.","Janney received 19,838,511 votes for; Rossi 23,336,879; Sutherland 23,337,104; broker non-votes 3,770,846.","Ratification of KPMG as independent auditor for FY2025: 27,723,997 for, 14,761 against, 5,354 abstentions.","Advisory vote on named executive officer compensation approved: 22,543,683 for, 1,423,437 against, 6,146 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158344,"accession_number":"0001711279-25-000048","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.","Both HSV-1-based vectors transduced keratinocytes with dose-dependent target protein expression and no cytotoxicity.","KB111 functionally corrected ATP2C1 siRNA knockdown in keratinocytes, reversing F-actin loss (p<0.05).","Topical administration in mice showed proper localization of ATP2C1 and ATP2A2 with minimal toxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158343,"accession_number":"0001711279-25-000045","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.","Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.","European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.","Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.","FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":88183000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158342,"accession_number":"0001711279-25-000037","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech Presents Preclinical Data on KB801 Gene Therapy for Neurotrophic Keratitis at ARVO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB801 is a topical HSV-1-based vector encoding human NGF for neurotrophic keratitis, disclosed in an 8-K filed May 5, 2025.","In vitro, KB801 transduction of primary human corneal epithelial cells resulted in dose-dependent secretion of mature, functional NGF protein.","In a murine corneal wound model, a single topical KB801 dose produced higher peak NGF (491 pg/eye) and prolonged exposure (t1/2 55.5 hrs) vs. rhNGF (t1/2 83 min).","After eight weekly topical KB801 doses, eyes showed only mild inflammatory infiltrate with no necrosis; all resolved by 27 days post-treatment.","Poster presented at ARVO 2025 Annual Meeting in Salt Lake City, Utah on May 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158341,"accession_number":"0001711279-25-000029","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.","Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.","First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176729,"accession_number":"0001711279-25-000013","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.","Final EC decision anticipated in Q2 2025, applicable to EU member states plus Iceland, Norway, Liechtenstein.","Positive opinion based on Phase 1/2 GEM-1 and Phase 3 GEM-3 data showing durable wound closure.","Company expects first European launch in Germany around mid-2025, followed by France later in 2025.","VYJUVEK previously approved by FDA in May 2023 for DEB patients aged 6 months and older in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176728,"accession_number":"0001711279-25-000009","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).","Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.","Cash, cash eq & investments $749.6M as of Dec 31, 2024.","Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.","FY2025 non-GAAP R&D+SG&A guidance $150-175M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":290515000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193546,"accession_number":"0001711279-24-000065","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.","Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.","Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.","Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.","Enrollment ongoing; detailed results to be presented at future scientific meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193545,"accession_number":"0001711279-24-000062","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.","Gene delivery confirmed: 39% of airway cells AAT-positive post-dose vs 0% at baseline.","KB407 for CF: Phase 1 CORAL-1 granted conditional sanctioning by CFF TDN; safe and well tolerated.","KB407 enrolling Cohort 3 (4 daily doses); data expected 1H 2025.","No serious adverse events in either program; all adverse events mild to moderate and transient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193544,"accession_number":"0001711279-24-000055","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.","Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.","Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.","JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.","Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":199376000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209855,"accession_number":"0001711279-24-000045","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.","75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.","No drug-related serious adverse events; adverse events were mild-to-moderate and transient.","Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.","Improvements also seen in crepiness, hydration, and radiance in both cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209854,"accession_number":"0001711279-24-000038","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.","Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.","Cash and investments $628.9M at June 30, 2024; strong balance sheet.","On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).","Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":115535000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228053,"accession_number":"0001711279-24-000027","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech stockholders elect directors, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Suma M. Krishnan, Julian S. Gangolli, and Catherine Mazzacco elected with 21.1M, 17.2M, and 20.4M votes for, respectively.","Ratification of KPMG as independent auditor for FY2024: 24.8M for, 7.4K against, 22.8K abstentions.","Advisory approval of named executive officer compensation for FY2023: 21.7M for, 851.7K against, 7.0K abstentions.","Broker non-votes of 2.2M for director election and say-on-pay; no broker non-votes on auditor ratification.","All proposals passed with strong majority support; no material changes to board or governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228052,"accession_number":"0001711279-24-000023","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech presents preclinical ocular gene therapy data at ARVO 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Subretinal and suprachoroidal injections achieved widespread mCherry expression across the retina in mice.","Vector transduced both photoreceptors (RHO+) and RPE cells (RPE65+) with minimal inflammation.","Intravitreal injection resulted in mCherry signal in cornea, iris, and ciliary body, not retina.","Low systemic dissemination detected; platform shows potential for inherited retinal diseases (IRDs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228051,"accession_number":"0001711279-24-000018","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.","VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.","Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.","Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.","Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":45250000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246808,"accession_number":"0001711279-24-000009","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.","FDA aligned on single-arm study to approve B-VEC eyedrops for ocular DEB in ~10 patients; study starts 2H 2024.","Cash & investments $594.1M at year-end; net income $8.7M in Q4 vs net loss of $32.1M in prior-year quarter.","First patient dosed in Phase 1 KB408 for AATD; FDA granted ODD. Interim data expected 2H 2024.","FY2024 non-GAAP R&D+SG&A guidance $150M-$175M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":50699000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264252,"accession_number":"0001711279-23-000074","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.","Net income $80.7M ($2.79 diluted EPS) vs net loss ($29.9M) year-ago; includes $100M gain on PRV sale.","Cash, equivalents and investments $598.6M; R&D expense $10.6M; SG&A $23.7M.","Pipeline: Cohort 1 complete in Phase 1 KB407 (CF); first patient dosed in Phase 1 KB707 (solid tumors); IND cleared for KB408 (AATD).","B-VEC filed for EU marketing authorization; Japan extension study dosed 5 patients; PRV sold for $100M; ASTRA facility operational."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":8556000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281497,"accession_number":"0001711279-23-000069","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Krystal Biotech Chief Commercial Officer Andrew Orth resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Orth resigned as Chief Commercial Officer, effective August 2, 2023.","No successor has been announced; reason for departure not disclosed.","The resignation is reported under Item 5.02 of Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281496,"accession_number":"0001711279-23-000067","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.","Cash, cash equivalents and investments $505.9M as of June 30, 2023.","Net loss $33.2M ($1.25 per share) vs $28.1M ($1.10 per share) in Q2 2022.","First CF patient dosed with KB407 in Phase 1 trial; KB707 IND accepted with Fast Track designation.","Positive coverage from UnitedHealthcare and other national/regional health plans for VYJUVEK."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281495,"accession_number":"0001711279-23-000061","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech expands to oncology; FDA accepts IND for KB707 for solid tumors","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted IND for KB707, a modified HSV-1 vector delivering IL-12 and IL-2 for solid tumors.","Two formulations: intratumoral injection for accessible tumors and inhaled (nebulized) for lung delivery.","Phase 1 Opal 1 study to start 2H 2023; amendment for inhaled formulation expected in 2H 2023.","Preclinical data showed antitumor responses in checkpoint-inhibitor-refractory mouse models.","Investor conference call on July 27, 2023 at 8:00 AM ET to discuss KB707 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300330,"accession_number":"0001711279-23-000044","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Krystal Biotech stockholders elect three Class III directors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Krish S. Krishnan, Kirti Ganorkar, and Christopher Mason elected as Class III directors for three-year terms.","Ratification of KPMG as independent auditor for FY2023 approved (22,098,460 for, 2,547 against).","Advisory vote on named executive officer compensation approved (18,759,786 for, 907,235 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300329,"accession_number":"0001711279-23-000039","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Krystal Biotech raises $160M in PIPE at $92.50/share for VYJUVEK launch and pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,729,729 shares at $92.50 each to institutional investors; gross proceeds ~$160M.","PIPE led by Avoro Capital Advisors and Redmile Group, with Braidwell LP and Frazier Life Sciences.","Proceeds to fund VYJUVEK commercialization, clinical pipeline, business development, and working capital.","Company expects to fund operations through end of 2026; retains optionality on Priority Review Voucher.","Registration statement for resale of shares to be filed within 60 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300328,"accession_number":"0001711279-23-000037","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Krystal Biotech's VYJUVEK gene therapy for DEB; first redosable gene therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval of VYJUVEK (beremagene geperpavec-svdt) for dystrophic epidermolysis bullosa (DEB) patients aged 6 months+.","Phase 3 GEM-3 trial met primary endpoint of complete wound healing at six months and key secondary endpoint at three months.","First-ever redosable gene therapy approved and first FDA-approved medicine for DEB (both recessive and dominant).","Rare Pediatric Disease Priority Review Voucher granted by FDA.","U.S. commercial launch expected Q3 2023; EU filing planned H2 2023, Japan launch targeted 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300327,"accession_number":"0001711279-23-000033","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.","RDEB patient's wound burden decreased 80-90%, reverted from severe to intermediate generalized phenotype.","No significant adverse events attributed to B-VEC; treatment well tolerated.","RDEB patient showed systemic improvements: increased height, weight, and serum albumin levels.","Data presented at ISID meeting in Tokyo, May 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300326,"accession_number":"0001711279-23-000031","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.","Cash, equivalents & investments $355.5M at March 31, 2023.","R&D expense $12.3M (up from $9.3M); G&A expense $24.0M (up from $15.9M).","PDUFA date for B-VEC Biologics License Application is May 19, 2023; labeling discussions started in April.","Topical B-VEC in eye under compassionate use showed vision improvement from hand motion to 20/40 at 7 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300325,"accession_number":"0001193125-23-137744","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Krystal Biotech enters $150M ATM equity offering with Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Cowen for at-the-market offering of up to $150M common stock.","Cowen receives 3.0% commission on gross proceeds from each sale; no obligation to sell.","Shares offered under existing shelf registration; proceeds for general corporate purposes.","Either party may suspend or terminate the offering with notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300324,"accession_number":"0001711279-23-000025","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech reports positive ocular data from compassionate use of B-VEC in DEB patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topical B-VEC achieved full corneal healing by 3 months and improved visual acuity from hand motion to 20/40 at 7 months.","No drug-related adverse events observed; treatment was well tolerated in the patient.","Patient had recurrent cicatrizing conjunctivitis; ocular complications affect >50% of recessive DEB patients.","Company plans to engage regulators to expand B-VEC utility for ocular DEB manifestations.","Ongoing preclinical studies evaluating intravitreal and subretinal deliveries for other ocular diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320355,"accession_number":"0001711279-23-000014","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Krystal Biotech appoints Catherine Mazzacco to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 9 directors; Catherine Mazzacco appointed as independent Class I director effective March 6, 2023.","Mazzacco will serve on the Nominating and Corporate Governance committee and stand for election at 2024 annual meeting.","She previously served as CEO & President of LEO Pharma and SVP at GE HealthCare, with 25+ years at Abbott Laboratories.","No material transactions or arrangements between Mazzacco and the company; standard director compensation applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320354,"accession_number":"0001711279-23-000010","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $383.8M at Dec 31, 2022.","Net loss $140.0M for FY2022 vs $69.6M in FY2021; diluted EPS $(5.49) vs $(3.13).","B-VEC PDUFA date set for May 19, 2023; all FDA inspections complete.","Phase 3 GEM-3 trial results for B-VEC published in New England Journal of Medicine.","Plans to initiate four pipeline trials in 2023 across dermatology, respiratory, aesthetics."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320353,"accession_number":"0001711279-23-000003","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech receives 3-month FDA BLA review extension for B-VEC; new PDUFA date May 19, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended PDUFA date for B-VEC (beremagene geperpavec) to May 19, 2023 due to major amendment from manufacturing info.","FDA indicated no Advisory Committee meeting and no REMS program needed for B-VEC application.","All pre-approval inspections of clinical sites and internal facilities completed successfully.","Labeling discussions proposed for no later than April 20, 2023.","CEO expresses disappointment but commits to working with FDA and continuing commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338501,"accession_number":"0001711279-22-000064","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.","Mean Subject Satisfaction Score change from baseline ranged from 1.6 to 1.85 points at 7-9 months.","Responder rate 62-70% based on Subject Satisfaction Score ≥1 point change; Investigator Assessments showed clinically meaningful difference in 70-76% of treated cheeks.","Plan to initiate Phase 2 PEARL-2 study in 1H 2023 for fine lines and wrinkles.","All adverse events were injection-site related, transitory, mild or moderate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338500,"accession_number":"0001711279-22-000061","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q3 net loss $29.9M; B-VEC BLA with Priority Review accepted, PDUFA Feb 17, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments $407M at quarter end; net loss $29.9M ($1.17 per share) vs $15.6M loss in Q3 2021.","FDA accepted B-VEC BLA for dystrophic epidermolysis bullosa with Priority Review; PDUFA target Feb 17, 2023.","No Advisory Committee meeting or REMS needed after mid-cycle review; EMA Pediatric Committee gave positive opinion.","R&D spent $11.5M (Q3 2022); pipeline: KB407 (CF) IND accepted, dosing starts Q4 2022; KB105, KB104, KB301 advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338499,"accession_number":"0001711279-22-000055","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"KB407 CF gene therapy data: human CFTR expression 106–440% of endogenous in NHPs; IND accepted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KB407 transduced ciliated, club, and goblet cells in NHP airways; no transduction of basal cells.","Human CFTR transcript levels reached 106–440% of endogenous NHP CFTR in lung biopsies.","No adverse findings in GLP toxicology study; NOAEL at highest dose tested.","FDA accepted KB407 IND in July 2022.","No significant cytokine induction in human CF cells after KB407 transduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355871,"accession_number":"0001711279-22-000052","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["7.01","8.01","99.1","9.01"],"status":"ready","headline":"FDA accepts Krystal Biotech's BLA for B-VEC with Priority Review; PDUFA Feb 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for B-VEC (gene therapy) to treat dystrophic epidermolysis bullosa (DEB).","Granted Priority Review; PDUFA target action date set for February 17, 2023.","FDA stated it does not currently plan to hold an advisory committee meeting on this BLA.","B-VEC previously received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations.","Company plans to submit marketing authorization application to EMA in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355870,"accession_number":"0001711279-22-000050","cik":1711279,"company_name":"Krystal Biotech, Inc.","ticker":"KRYS","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.","Filed BLA for B-VEC (DEB therapy) with FDA on June 22, 2022.","FDA accepted IND for KB407 (cystic fibrosis); Phase 1 trials expected 2H 2022.","R&D expense $10.9M, G&A $17.9M; losses reflect increased commercial prep.","Pipeline: KB105 dosing to resume 2H 2022; KB104 IND later 2022; KB301 Phase 2 in Q4 2022/Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9090082723.099667,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-08T23:59:59+00:00|355870"}